Valence (chemistry)

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Retrieved on: 
Thursday, March 7, 2024

“I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points: 
  • “I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
  • This marks the first marketing approval milestone for CSL and Arcturus since signing the Collaboration and License agreement in November 2022.
  • In November 2023, Arcturus received Orphan Drug Designation from the U.S. FDA for ARCT-032, for the treatment of Cystic Fibrosis.
  • We have achieved a total of approximately $396.0 million in upfront payments and milestones from CSL as of December 31, 2023.

Moisturizing Is Vital to Healthy Skin

Retrieved on: 
Wednesday, September 7, 2022

BOCA RATON, Fla., Sept. 7, 2022 /PRNewswire/ -- Moisturizing brings out healthy-looking skin.

Key Points: 
  • Moisturizing decreases the chances of having dry or oily skin, which can develop into skin conditions, such as acne," said Gianluca Zin, founder of Venezia1920, a global beauty brand based in Venice, Italy.
  • "We have a full line of healthier skincare products, including our Super Moisturizing creams," Zin said.
  • "First, our Super Moisturizing Cream With Aloe Vera and Hyaluronic Acidis a highly moisturizing cream for younger skin that can help prevent dry or oily skin," Zin said.
  • Venezia 1920 also has Super Moisturizing Anti-Aging Cream with Tetravalent, which is for extremely dry skin.

FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women

Retrieved on: 
Wednesday, September 7, 2022

Group B Streptococcus (GBS) is a common bacterium that can cause potentially devastating diseases in infants, including sepsis, pneumonia and meningitis, during the first three months of life.

Key Points: 
  • Group B Streptococcus (GBS) is a common bacterium that can cause potentially devastating diseases in infants, including sepsis, pneumonia and meningitis, during the first three months of life.
  • Vaccines given to pregnant women (maternal immunization) that are intended to prevent illness in young infants rely on this process of transplacental antibody transfer.
  • A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
  • Group B Streptococcus infection causes an estimated 150,000 preventable stillbirths and infant deaths every year.

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
Tuesday, September 6, 2022

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.